CD8A and myeloid sarcoma: Therapy-naïve MS patients exhibit a preponderance of Th1 over Th2 immune function, excessive expression of costimulatory molecules such as CD80 on B cells, dysfunctional CD8 and CD4 regulatory T cells, and a disrupted type I IFN system [1–4].